Page 3 - Fady Ibraham Malik News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fady ibraham malik. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fady Ibraham Malik Today - Breaking & Trending Today

HC Wainwright Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cytokinetics in a research report issued on Thursday, May 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($1.16) for the quarter, up […] ....

United States , Raymond James , Fady Ibraham Malik , Johnt Henderson , Financial Services Group Inc , Needham Company , Third Bancorp , Cytokinetics Incorporated , Mutual Of America Capital Management , Cytokinetics Company Profile , Securities Exchange Commission , Quadrant Capital Group , Fifth Third Bancorp , Free Report , Get Free Report , Stock Down , State Retirement , Pension System , Capital Group , America Capital Management , Services Group , Ibraham Malik , Exchange Commission , Director John , Cytokinetics Daily ,

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has received a consensus rating of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12 month price objective among […] ....

United States , Fady Ibraham Malik , Johnt Henderson , Bessemer Group Inc , Securities Exchange Commission , Third Bancorp , Sage Rhino Capital , Entrypoint Capital , Cytokinetics Incorporated , Fifth Third Bancorp , Get Free Report , Truist Financial , Ibraham Malik , Exchange Commission , Director John , Point Capital , Get Free , Cytokinetics Daily ,

Needham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. CYTK has been the subject of several other research reports. JMP Securities lowered their price […] ....

Johnt Henderson , Fady Ibraham Malik , Victory Capital Management Inc , Vanguard Group Inc , Securities Exchange Commission , Legato Capital Management , Cytokinetics Company Profile , Needham Company , Cytokinetics Incorporated , Free Report , Moderate Buy , Get Free Report , Ibraham Malik , Exchange Commission , Director John , Minvest Partners , Capital Management , Victory Capital Management , Cytokinetics Daily ,

Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Raymond James from $92.00 to $70.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CYTK. Mizuho reduced their price target on shares […] ....

Johnt Henderson , Raymond James , Fady Ibraham Malik , Cytokinetics Company Profile , Securities Exchange Commission , Bessemer Group Inc , Cytokinetics Incorporated , Third Bancorp , Entrypoint Capital , Needham Company , Fifth Third Bancorp , Sage Rhino Capital , Free Report , Truist Financial , Moderate Buy , Get Free Report , Ibraham Malik , Exchange Commission , Director John , Point Capital , Cytokinetics Daily ,

Barclays Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $95.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Barclays from $100.00 to $95.00 in a report issued on Thursday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $94.00 […] ....

Fady Ibraham Malik , Johnt Henderson , Sage Rhino Capital , Fifth Third Bancorp , Entrypoint Capital , Cytokinetics Incorporated , Third Bancorp , Cytokinetics Company Profile , Bessemer Group Inc , Free Report , Truist Financial , Moderate Buy , Get Free Report , Director John , Ibraham Malik , Point Capital , Cytokinetics Daily ,